摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2,3-epoxyplumbagin | 188675-38-9

中文名称
——
中文别名
——
英文名称
2,3-epoxyplumbagin
英文别名
6-Hydroxy-1a-methyl-1a,7a-dihydronaphtho[2,3-b]oxirene-2,7-dione;3-hydroxy-7a-methyl-1aH-naphtho[2,3-b]oxirene-2,7-dione
2,3-epoxyplumbagin化学式
CAS
188675-38-9
化学式
C11H8O4
mdl
——
分子量
204.182
InChiKey
XYOABSOIKCDDDO-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    442.6±45.0 °C(Predicted)
  • 密度:
    1.544±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.4
  • 重原子数:
    15
  • 可旋转键数:
    0
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.27
  • 拓扑面积:
    66.9
  • 氢给体数:
    1
  • 氢受体数:
    4

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    2,3-epoxyplumbagin硫酸 作用下, 反应 0.25h, 以46%的产率得到茅膏菜醌
    参考文献:
    名称:
    Preparation of Naphthoquinone Derivatives from Plumbagin and Their Ichthyotoxicity.
    摘要:
    各种萘醌衍生物是从天然产物5-羟基-2-甲基-1,4-萘醌(铅醌)中制备的;这些衍生物主要通过金属氧化剂(如醋酸铅四乙酯)在多种羧酸存在下,通过碳-碳键形成在C-3位进行取代。卤素化化合物的鱼毒性比铅醌更强,但其他衍生物的活性较低。
    DOI:
    10.1248/cpb.45.437
  • 作为产物:
    描述:
    兰雪醌双氧水potassium carbonate 作用下, 以 乙醇 为溶剂, 反应 2.0h, 以60%的产率得到2,3-epoxyplumbagin
    参考文献:
    名称:
    Dinda; Hajra; Das, Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 1998, vol. 37, # 7, p. 672 - 675
    摘要:
    DOI:
点击查看最新优质反应信息

文献信息

  • Valderrama, Jaime A.; Gonzalez, M. Florencia; Torres, Cristian, Heterocycles, 2003, vol. 60, # 10, p. 2343 - 2348
    作者:Valderrama, Jaime A.、Gonzalez, M. Florencia、Torres, Cristian
    DOI:——
    日期:——
  • Extracts of Cranberry and Methods of Using Thereof
    申请人:Alberte Randall S.
    公开号:US20100028469A1
    公开(公告)日:2010-02-04
    The present disclosure relates in part to extracts of cranberry ( Vaccinium macrocarpon ) comprising an enriched amount of certain compounds having anti-infective activity, e.g. antibacterial and/or antifungal activity, e.g. activity against C. albicans . Another aspect of the disclosure relates to combined cranberry and cinnamon extracts. In certain embodiments, these combined extracts have been optimized to control urinary tract infections caused by E. coli, S. aureus and C. albicans . Certain embodiments of the extract are enriched in bioactive compounds that have been shown to inhibit C. albicans adhesion and/or biofilm formation and its growth in vitro. In another aspect of the disclosure, the extracts are enriched in bioactives derived from cranberry and cinnamon that have been shown to inhibit the attachment and the growth of common urinary tract pathogens like E. coli, S. aureus and C. albicans.
  • ANTI-CANCER LEAD MOLECULE
    申请人:KING ABDULLAH UNIVERSITY OF SCIENCE AND TECHNOLOGY
    公开号:US20140107196A1
    公开(公告)日:2014-04-17
    Derivatives of plumbagin can be selectively cytotoxic to breast cancer cells. Derivative ‘A’ (Acetyl Plumbagin) has emerged as a lead molecule for testing against estrogen positive breast cancer and has shown low hepatotoxicity as well as overall lower toxicity in nude mice model. The toxicity of derivative ‘A’ was determined to be even lower than vehicle control (ALT and AST markers). The possible mechanism of action identified based on the microarray experiments and pathway mapping shows that derivative ‘A’ could be acting by altering the cholesterol-related mechanisms. The low toxicity profile of derivative ‘A’ highlights its possible role'as future anti-cancer drug and/or as an adjuvant drug to reduce the toxicity of highly toxic chemotherapeutic'drugs.
  • CHOLESTERYL ESTER TRANSFER PROTEIN (CETP) INHIBITION IN THE TREATMENT OF CANCER
    申请人:KING ABDULLAH UNIVERSITY OF SCIENCE AND TECHNOLOGY
    公开号:US20180049997A1
    公开(公告)日:2018-02-22
    In one embodiment, the invention provides methods of treatment which use therapeutically effective amounts of Cholesteryl Ester Transfer Protein (CETP) inhibitors to treat a variety of cancers. In certain embodiments, the inhibitor is a CETP-inhibiting small molecule, CETP-inhibiting antisense oligonucleotide, CETP-inhibiting siRNA or a CETP-inhibiting antibody. Related pharmaceutical compositions, kits, diagnostics and screens are also provided.
  • US9890106B2
    申请人:——
    公开号:US9890106B2
    公开(公告)日:2018-02-13
查看更多